← Bausch & Lomb (BLCO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Bausch & Lomb (BLCO)
Ophthalmic Goods · market cap $6.1B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Bausch & Lomb (BLCO) is a large-cap Canadian eye health company with ~$5.1B in 2025 revenue across contact lenses, lens care, pharmaceuticals, and surgical products. The company carries a heavy debt load of ~$4.8B net debt against only $268M cash, and has posted widening net losses despite solid top-line growth. Its pipeline spans over 30 clinical-stage programs across inflammation, glaucoma, dry eye, and allergic conjunctivitis, with a key Phase 2 catalyst for a Lifitegrast/Perfluorohexyloctane fixed-dose combination expected around November 2026.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Loteprednol Etabonate Gel (BID) | Phase 3 | Inflammation |
| Bromfenac Ophthalmic Solution | Phase 3 | Pain |
| bromfenac ophthalmic solution 0.06% | Phase 2 | Dry Eye Disease |
| brinzolamide 1% ophthalmic suspension | Phase 3 | Glaucoma |
| 0.5% Loteprednol Etabonate Ophthalmic Ointment | Phase 3 | Ocular Inflammation |
| BOL-303259-X | Phase 3 | Ocular Hypertension |
| 0.59 mg fluocinolone acetonide intravitreal implant | Phase 2 | Diabetic Macular Edema |
| Bromfenac | Phase 3 | Postoperative Complications |
| Loteprednol etabonate | Phase 3 | Cataract |
| Besivance | Phase 3 | Bacterial Conjunctivitis |
| Loteprednol Etabonate Gel (TID) | Phase 3 | Inflammation |
| EM-100 | Phase 3 | Allergic Conjunctivitis |
| Brimonidine Tartrate | Phase 3 | Hyperemia |
| Latanoprostene bunod | Phase 3 | Glaucoma |
| Bepotastine besilate | Phase 3 | Seasonal Allergic Rhinitis |
| Ketotifen/naphazoline | Phase 3 | Allergic Conjunctivitis |
| Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution | Phase 3 | Seasonal Allergic Conjunctivitis |
| ecabet ophthalmic solution | Phase 2 | Dry Eye Disease |
| Loteprednol Etabonate Ophthalmic Gel dosed TID | Phase 3 | Cataract |
| Bromfenac Ophthalmic Solution A | Phase 3 | Dry Eye Syndrome |
Price & technical context
3-month
-1.3%
6-month
+1.6%
12-month
+12.4%
52-wk range
$14.32–$18.60
vs 50-day MA
-0.7%
vs 200-day MA
+1.8%
Realized vol
28.8%
Max drawdown
-47.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BLCO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.